Gilead Sciences, sacituzumab govitecan-hziy, Trodelvy, TROPiCS-02
Sacituzumab govitecan-hziy is approved by FDA for HR-positive breast cancer
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
Immunomedics Inc, mUC, platinum-containing chemotherapy, programmed death receptor-1, sacituzumab govitecan, Trodelvy, TROPHY
Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally advanced or metastatic urothelial cancer (mUC) who had previously receiv..
Immunomedics Inc, mTNBC, NCT02574455, sacituzumab govitecan, Trodelvy
Sacituzumab govitecan receives FDA approval for triple-negative breast cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA clearance for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior ..